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Abstract: Exercise-induced bronchoconstriction (EIB) is very common in both patients with 
asthma and those who are otherwise thought to be normal. The intensity of exercise as well 
as the type of exercise is important in producing symptoms. This may make some types of 
exercise such as swimming more suitable and extended running more difficult for patients 
with this condition. A better understanding of EIB will allow the physician to direct the patient 
towards a type of exercise and medications that can result in a more active lifestyle without 
the same concern for resulting symptoms. This is especially important for schoolchildren who 
are usually enrolled in physical education classes and elite athletes who may desire to participate 
in competitive sports. Fortunately several medications (short- and long-acting β2-agonists, 
cromolyn, nedocromil, inhaled corticosteroids, and more recently leukotriene modifiers) have 
been shown to be effective in preventing or attenuating the effects of exercise in many patients. 
In addition, inhaled β2-agonists have been shown to quickly reverse the airway obstruction that 
develops in patients and continue to be the reliever medications of choice. Inhaled corticosteroids 
are increasingly being recommended as regular therapy now that the role of inflammation and 
airway injury has been identified in EIB. With the discovery that there is a release of mediators 
such as histamine and leukotrienes from cells in the airway following exercise with resulting 
airway obstruction in susceptible individuals, interest has turned to attenuating their effects with 
mediator antagonists especially those that block the effects of leukotrienes. Studies with an oral 
leukotriene antagonist, montelukast, have shown beneficial effects in adults and children aged 
as young as 6 years with EIB. These effects can be demonstrated as soon as two hours and as 
long as 24 hours after administration without a demonstrated loss of a protective effect after 
months of treatment. The studies leading up to and resulting in an approval of montelukast for 
EIB for patients aged 15 years and older are reviewed in this paper.
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Probably the first description of exercise-induced bronchoconstriction (EIB) was 
during the 2nd century when the Greek physician Aretaeus the Cappadocian wrote: 
“If  from running, and exercise, and labor of  any kind a difficulty of  breathing follows it is 
termed asthma”.1 Fast-forward to the current era where this condition not only affects 
millions worldwide but has been an issue for the International Olympic Committee.2,3 
Their concern largely results from the use of performance-enhancing drugs during 
athletic competition. This response is not surprising since many bronchodilators such 
as salbutamol (albuterol) and methyl xanthenes (theophylline, aminophylline) can 
have effects on the cardiovascular system in higher than usually prescribed doses. Therapeutics and Clinical Risk Management 2009:5 924
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However, in a recent review of 19 placebo-controlled studies, 
it was found that in 17 of the studies the effects of inhaled 
β2-agonists in doses commonly used to prevent EIB did not 
result in ergogenic effects in competitive athletes.4 Although 
the World Anti-Doping Agency has included β2-agonists in 
their list of prohibited drugs, both short- and long-acting 
β2-agonists are exempt when inhaled.5 This information, 
along with pre-competition testing,6 has allowed athletes 
with EIB to compete in Olympic Sports without the threat 
of disqualification as has occurred in the past. Concerns 
that athletes taking inhaled corticosteroids (ICS) for asthma 
control may be using medications that increase muscle 
mass as can be obtained from anabolic steroids have also 
been dismissed as appropriate doses of ICS have shown the 
ability to reduce the severity of EIB without this or other 
adverse effects.7
Although EIB and exercise-induced asthma (EIA) are 
often used interchangeably, it is becoming common to 
use EIB for patients who have a diagnosis of asthma and 
wheeze after exercise and use EIA in individuals who only 
have airway obstruction following exercise, but are otherwise 
free of asthma. EIB has also been called exercise-induced 
airway narrowing8 by McFadden who states that these terms 
“describe a condition in which vigorous physical activity 
triggers acute airway narrowing in people with heightened 
bronchial reactivity”. He further points out that “exercise in 
EIA merely serves as the means by which ventilation rises. 
Hyperpnea is the key element, and it is immaterial how it 
comes about.”8
EIB is considered a form of airway hyperresponsiveness 
(AHR) and its expression increases and decreases in relation-
ship to the degree of underlying airway reactivity9 and the 
severity of the underlying asthma.10 The importance of AHR 
in EIB and asthma was emphasized by a recent study which 
showed that children with increased airway responsiveness 
in late infancy and childhood had a greater risk of developing 
asthma than their counterparts who did not have increased 
airway responsiveness in infancy.11
EIB has been reported present in as few as 40% and 
as many as 90% of  patients with asthma.12 Some of this 
difference can be accounted for by the severity of  the patient’s 
asthma, the intensity, the duration, as well as the type of 
exercise challenge employed.
In patients with asthma, exercise-induced symptoms can 
be used as a marker of incomplete asthma control indicating 
a need for additional controller medications.
Individuals with allergic rhinitis without asthma have been 
reported to have a prevalence of EIB of up to 40%12 and can 
be found in up to 13% of otherwise normal individuals when 
the challenge test is adequate. Therefore this is a common 
condition which may go unrecognized for years especially in 
individuals who do not or choose not to exercise.
Interestingly the prevalence of EIB and AHR are increased 
in elite athletes.13 It is suspected that the repeated high 
ventilation required during training may irritate the airways 
and result in mediator release and airway injury. This would 
be particularly likely during periods of  air pollution, exposure 
to pollens, or extreme cold air. This effect may be somewhat 
reversible after cessation of endurance training.14
EIB usually occurs following 5–8 minutes of vigorous 
exercise, enough to result in prolonged hyperventilation. 
Frequently the degree of EIB is recorded as the maximum 
percent fall in forced expiratory volume in one second (FEV1) 
from baseline following the exercise period.15 At other times 
the degree of airway obstruction may be recorded as the 
entire time from when lung function as demonstrated by a 
change in FEV1 falls below baseline until this value returns 
to 5% of pre-exercise FEV1 or the patient requires relief from 
an inhaled short-acting β2-agonist (SABA). This measure-
ment takes into account the entire time that the subject has 
airway obstruction and not just the maximum effect of the 
test16 (Figure 1).
To document EIB, patients can be exercised in a laboratory 
on a treadmill or exercycle for 5–8 minutes at a heart rate 
estimated to approach 80%–90% of maximum (approximates 
80% oxygen consumption), which is determined by the 
patients’ age. This level of exercise is usually enough to 
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Figure 1 end points used to assess the degree of exercise-induced bronchoconstric-
tion. The following end points were assessed: the area under the curve for the percent 
decrease in Fev1 in the first 60 minutes after exercise, the maximal decrease in FEV1 
after exercise, and the time from the maximal decrease in Fev1 to the return to within 
5% of the Fev1 value before exercise.
Abbreviation: Fev1, forced expiratory volume in one second.Therapeutics and Clinical Risk Management 2009:5 925
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induce EIB in susceptible subjects.15 The effect on the airways 
maybe further intensified by having the subject breathe cool 
dry air through their mouth while exercising.17 This can be 
accomplished by inflating a breathing bag with compressed 
air from which the subjects breathes. A two-way valve allows 
for air to be exhaled into the laboratory. To insure the subject 
is breathing through the mouth a nose clip must be used. 
Some subjects are able with nasal breathing, to warm and 
humidify the air enough that it may be difficult to demon-
strate a significant fall in FEV1 as a response to the challenge 
test.17 In a majority of subjects with mild asthma or in those 
only having EIB, the fall in FEV1 is usually less profound, 
self limited, and resolves within an hour without medica-
tion. Other subjects may need to be rescued with an inhaled 
β2-adrenergic bronchodilator such as salbutamol (albuterol) 
if they become extremely symptomatic or have a profound 
fall in FEV1 which does not reverse quickly.
Since the cause of the airway narrowing is not a 
result of the exercise per se, but as a result of prolonged 
hyperventilation, it is possible to induce a similar response 
in the airway with isocapnic voluntary hyperventilation.18,19 
Also hypertonic aerosols19,20 can be used to induce an airway 
response in patients with EIB. However these tests are an 
indirect test of EIB and should be considered more of a 
measurement of AHR even though there may be excellent 
correlation in many patients who have EIB.
It is possible to demonstrate that a patient has EIB 
during typical exercise in a real-world setting. One common 
method is to have the individual exercise on a playground or 
athletic field for about five minutes using a peak flow meter 
to obtain flow values before and after the exercise period. A fall 
of peak expiratory flow (PEF) of 15% or greater would 
indicate a change in air flow enough to suggest a diagnosis 
of EIB. However, it is important to remember that this real-
world challenge may not duplicate all exercise situations the 
subject is exposed to, nor be sufficiently vigorous to cause a 
15% fall in PEF or FEV1. It has been shown that the degree 
of EIB in children depends on the exercise load. A study of 
children who exercised at 85% of maximum showed a fall 
in FEV1 of 8.8%, whereas when they exercised at 95% of 
maximum, the fall in FEV1 was 25.1%.21 A false negative test, 
if suspicions of EIB are high, should be repeated in the labora-
tory under more controlled conditions as described before. 
If this is not feasible then a trial of an inhaled β2-agonist 
before exercise might result in a clinical response of block-
ing airway narrowing, which allows the patient to be active 
until more definitive testing can be done. In such situations, 
close follow up is very important because other respiratory 
conditions such as vocal cord dysfunction22 or other upper 
airway obstructions, as well as cardiovascular events, can be 
manifested during or immediately after exercise. In a study 
that reported the findings of 11 patients who reported cold 
air dyspnea with exercise, no bronchoconstriction could be 
demonstrated after exercise provocation, but capsaicin cough 
sensitivity was increased and end-tidal CO2 decreased among 
the patients.23 The authors concluded that exercise-induced 
dyspnea may be associated with hypocapnia from hyper-
ventilation and increased capsaicin cough sensitivity. The 
diagnosis of exercise-induced asthma should be questioned 
when the patient has no signs of bronchoconstriction. Many 
of these possible diagnoses can be ruled out by additional 
testing. However, spirometric evaluation remains the best test 
to consider initially. This in part is because only about 50% of 
patients can correctly assess their degree of airway obstruction 
when asked24 and it is the change in airway caliber which is 
measured by a change in FEV1 that is the hallmark of EIB.
Since EIB is considered a form of AHR by many inves-
tigators, most patients with this condition also respond with 
airway obstruction when challenged with bronchoprovocation 
agents such as inhaled hypertonic aerosols19 or methacholine.25 
More recently inhaled mannitol,26,27 although not yet approved 
for bronchoprovocation testing in all countries including the 
United States has been shown to correlate very well with 
standard exercise tests in both elite athletes26 and in asthma 
patients27 who have EIB.
The observation that cool and/or dry air increases the 
possibility of EIB led to two theories of its etiology that were 
debated for years.28,29 One theory concerned a cooling and the 
other a dehydration of the cells that line the airways. Recently 
EIB is believed to occur because of an injury to the airway 
epithelium.30 Increased concentrations of airway columnar 
epithelial cells, eosinophils, and leukotrienes were seen in 
induced sputum of subjects with EIB compared to those 
who did not have significant bronchoconstriction following 
exercise.31 In another study, the same group found decreased 
concentrations of prostaglandin E2 and thromboxaine D2 in 
the sputum of patients with EIB.32 In elite athletes it has been 
proposed that airway injury with resulting plasma exudation 
and cell movement into the airways occurs contributing to 
the pathogenesis of EIB.30,32 Stimuli such as prolonged hyper-
ventilation on an injured epithelium are believed to produce 
a dehydration and a resulting degranulation of airway cells 
with a release of inflammatory mediators such as histamine 
and leukotrienes. It is the effect of these mediators in the 
airway that lead to constriction of smooth muscles, stimula-
tion of mucous-producing glands, and microvascular leakage Therapeutics and Clinical Risk Management 2009:5 926
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with resulting airway edema. The end result is one of airway 
narrowing and the typical symptoms of asthma: wheezing, 
coughing, chest tightness, shortness of breath, and dyspnea 
following exercise.
Characteristically, symptoms begin within a few 
minutes after the exercise period is completed. The degree 
of  change in airway function is reflected by a measurable 
decrease in FEV1 or PEF of at least 10% although many 
believe there should be a change of 15% or greater. Following 
the maximum drop in FEV1, the values usually return to 
baseline spontaneously within one hour. However, when 
extreme airway obstruction occurs, improvement may need 
to be obtained with the inhalation of a β2-agonist such as 
salbutamol (albuterol). Actually both short- or long-acting 
β-agonists (LABAs) can result in an improvement in symp-
toms and a more rapid return of the FEV1 to normal.8
EIB occurs often after prolonged exercise such as distance 
running which would duplicate a 5–8 minute exercise test in 
the laboratory. Shorter periods of running such as a 100 m 
race, which does not result in prolonged hyperventilation is 
often insufficient to induce symptoms. Although both allergy 
and asthma occur in elite summer athletes,33 it has been 
thought that athletes who swim for exercise are not as likely 
to develop EIB as those that run. This was presumed to be 
because when swimming, the ambient air near the surface of 
the water is highly humidified and may be warmer. However, 
it has been shown that while swimming indoors in chlorinated 
pools, the athlete is exposed to chloramines which have 
been shown to be asthmagenic34 and a prevalence of EIB as 
high as 29% has been reported in competitive swimmers.35 
Nevertheless it is possible for athletes with asthma induced 
by running to win Olympic medals in swimming competi-
tions (Kurt Grote: Gold Medal winner at the 1996 Atlanta 
Olympics) and for many patients there are beneficial effects 
as well as potential adverse effects from swimming.34 
The prevalence of EIB and AHR are increased in some elite 
athletes.36,37 This may be due to the extreme hyperventila-
tion that occurs during training in some sports. Training all 
year in climates that require breathing cold dry air or during 
seasonal allergy periods for those athletes who are atopic may 
have injurious effects on the airways.38 Other observations 
have been made recently. A study reported a higher preva-
lence of methacholine-induced AHR in females (F: 60% vs 
M: 21.5%) and reported symptoms during exercise (F: 37.1% 
vs M: 16.9%), even though there was a similar prevalence 
of physician-diagnosed asthma in their male counterparts.39
In a study of children with mild asthma, exercise training 
decreased bronchial responsiveness to methacholine40 and 
some patients become less subject to the airway obstructive 
effects of exercise following exercise conditioning. This may 
be a result of better conditioning with a more efficient use of 
oxygen and less hyperventilation during exercise. It may be 
that decreasing exercise gradually allows for a slower rate of 
rehydration and warming of the airway. Following exercise 
in 40%–50% of patients with EIB there may be a refractory 
period of 1–3 hours during which additional exercise41 or 
hyperventilation42 does not induce airway obstruction at 
least to the same degree. This finding becomes an important 
consideration when doing repeated exercise challenges as 
might occur in clinical drug trials looking at duration of the 
pharmacotherapeutic effect of the medication being studied. 
Also this refractory period may allow athletes to decrease the 
effects of exercise prior to competition.43
For patients with more severe degrees of asthma, exercise 
without medication is often impossible. The degree of airway 
obstruction that pre-exists before exercise is such that they 
are unable to exercise sufficiently to develop EIB, although 
there is no relationship between baseline FEV1 and severity of 
EIB.44 Inactivity as a consequence of asthma is not considered 
to be acceptable in the asthma management guidelines45,46 
and indicates the need for additional controller medications 
in most patients so that their life can be normalized as much 
as possible. Recently a study showed that regular physical 
activity reduced the risk of asthma exacerbations in older 
(mean age 63 years) women.47 Although this prospective 
study was not able to evaluate this effect on the subgroup of 
patients with EIB enrolled in the study the beneficial effects 
of exercise on asthma was clearly demonstrated.
Fortunately there are several medications that can help 
the patient with EIB exercise at higher cardiovascular 
levels for longer periods of time. Most of these medications 
are well known pharmacotherapeutic agents used to treat 
persistent asthma. However, most have also been found to 
be effective in patients who have intermittent asthma with 
symptoms following exercise. Since asthma is considered by 
most experts as a heterogenous disorder, not all medications 
will work equally well in all patients.48,49 This review will 
briefly look at these medications and their effect on EIB but 
will focus on the leukotriene receptor antagonist (LTRA), 
montelukast, the latest to receive drug regulatory approval in 
many countries for the management of EIB in adults.
Medications
inhaled anticholinergics
Although useful drugs in treating chronic obstructive 
pulmonary disease (COPD), most studies with drugs in this Therapeutics and Clinical Risk Management 2009:5 927
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category have shown very little effect as monotherapy in 
most types of asthma. This is true in the majority of studies 
dating back to the 1980s in patients with EIB.50–53 Although 
immediately after inhalation there can be demonstrated a 
modest improvement in FEV1, presumably from a decrease in 
bronchomotor tone, there is little effect on the prevention of 
EIB and in the majority of patients they are not used as such.
inhaled corticosteroids
Because asthma is characterized by AHR, most patients who 
exercise to a significant level will have EIB. Because current 
asthma treatment guidelines recommend regular controller 
medications for all patients who have more than mild well 
controlled asthma45,46 many of these patients will be taking 
ICS already. The effect of ICS on airway inflammation in 
both adults and children when given for at least four weeks 
will in many cases be enough to decrease or eliminate EIB.54 
Therefore, before starting additional medications for EIB, 
it is important to be certain how well a patient’s asthma is 
being controlled with the medications they are supposed to 
be taking. Since adherence (compliance) with all asthma 
controller medications including ICS is extremely poor,55 
it is important to review the patient’s actual adherence to 
their previously prescribed medications. As obvious as it 
may seem, it is commonly overlooked in practice that the best 
medication, improperly or inadequately taken, will have a 
subtherapeutic effect. All that may be needed in such patients 
is to reestablish their prior treatment plan.
β-adrenergic agonists
Most patients respond well to β2-agonists for both the 
prevention of EIB when given prior to the exercise period or 
post-exercise to reverse the obstruction that has occurred.56 
The effect of these medications especially when taken by 
inhalation is rapid which results in their being the most com-
monly prescribed for patients with asthma and EIB. This is 
true of both SABAs and LABAs57,58 such as salmeterol59,60 
or formoterol.61,62 The later are usually used as controller 
medications, preferably with an ICS. However, as has been 
reported with SABAs, when LABAs are regularly taken, 
tolerance to their original effect63,64 rapidly develops. This 
often results in shorter times of protection although the 
protection is frequently sufficient to exercise 3–4 hours after 
administration.59 As a response to reports of an increase in 
deaths when patients have taken LABAs,65,66 a recent US 
Food and Drug Administration (FDA) advisory panel voted 
that the risk of taking single entity salmeterol and formoterol 
outweighed their benefit and recommended that LABAs 
only be used in combination with an ICS.67 This may result 
in the removal of single entity LABAs from the US market 
for the treatment of asthma. However since this increase 
in adverse effects from single entity LABAs has not been 
seen in patients with COPD, these drugs will still remain 
as a treatment option for EIB in the United States although 
when used, will be used off label. If elimination or further 
restriction of single entity LABAs occurs because patients 
with EIB have AHR, a combination of a LABA with an ICS 
is very likely to have additive effects and may result in a 
better outcome than using monotherapy alone. Many asthma 
experts believe that a LABA should always be used with an 
ICS, although there is inadequate evidence that doing so 
decreases risk of serious adverse events.67,68
Cromones
Cromolyn sodium and nedocromil sodium are not used 
as frequently today,69–71 although effective and approved 
in most countries for EIA. Their popularity waned in part 
because of the current availability of more effective, faster, 
longer acting, and easier to take medications. Because of 
their excellent safety profile, they were used extensively in 
children with EIB as well as in children with more persistent 
asthma. They can work alone or in combination when 
other medications have failed to block the airway response 
to exercise significantly. It is important to consider their 
use especially when other medications have been proven 
inadequate since their mechanism of action is different. They 
are now generic drugs in all countries and should also be 
considered when the expense of medication is a concern.
However, since the removal of chloroflurocarbon 
propellants and the current nonavailability of hydroflo-
roalkane inhalers for either medication, they will only 
be available as dry powder inhalers and a nebulizable 
solution, which further limits their availability. Currently 
they are available in some countries such as New Zealand 
and Australia in a dry powder formulation. The nebulized 
formulation is available in the US.
Leukotriene receptor antagonists 
and leukotriene synthesis inhibitors
With the recognition that elevated levels of leukotrienes 
are found in the airway of patients with EIB72,73 as well as 
in patients with acute and chronic asthma,74 the effects of 
LTRA75–78 and inhibitors of leukotriene synthesis79,80 began to 
be explored. Zafirlukast, the first LTRA to be approved in the 
US for asthma, showed protection against EIB in both adults81 
and children82 when given eight hours before an exercise test. Therapeutics and Clinical Risk Management 2009:5 928
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Pranlukast showed a similar protective effect after 14 days of 
treatment in a Japanese study.83 Other inhibitors of the activity 
of leukotrienes such as ziluton, a leukotriene synthesis inhibi-
tor, have also shown beneficial effects in patients with EIB.80 
In most countries, only the LTRA montelukast has received 
approval by drug regulatory agencies for prevention of EIB. 
What follows is a review of the studies that resulted in its 
approval in adults and studies that may lead to its approval 
in children.
Montelukast for eiB
Montelukast, a LTRA available as oral single daily medication, 
was first approved in the US in March 1998 for the treatment 
of persistent asthma in adults (10 mg) and children as young 
as one year of age (5 mg or 4 mg). Later in some countries it 
was given an approval for the treatment of allergic rhinitis and 
more recently approval for the prevention of EIB.
The duration of clinical effect of montelukast in treating 
persistent asthma was in part determined by using the model 
of EIB. In two separate exercise studies, it was found that 
there was an effect lasting for 24 hours after giving a single 
10 mg dose of montelukast in adults with EIB, even though 
the half life of montelukast in the blood is only about five 
hours.84 In a study published in the New England Journal 
of  Medicine,85 110 adults demonstrated a positive effect of 
montelukast on EIB for 12 weeks (Figure 2). In this study, sub-
jects were given either a placebo or montelukast 10 mg prior 
to exercising on a treadmill at a rate estimated to be 80% of 
maximum cardiac output for five minutes while breathing cool 
dry air. Following this challenge, subjects were observed for 
one hour to determine at what point their breathing returned to 
baseline. Patients who developed severe airway obstruction 
were allowed to use a SABA for relief during the 60 minute 
post-exercise observation period. Exercise challenges during 
the study were performed 20–24 hours post dosing at weeks 
4, 8, and 12 and at the end of a two-week wash out period. 
There was a 47.4% (p = 0.002) improvement in the monte-
lukast subjects over the placebo group in the area under the 
FEV1 curve during the first 60 minutes following exercise. 
After 12 weeks of treatment the patients on placebo had a 
mean maximum fall in FEV1 of greater than 30% after the 
exercise period whereas the patients pretreated with monte-
lukast had a 18% decrease. Those patients on montelukast 
had a more rapid return of airway function toward their 
baseline than those receiving a placebo and needed rescue 
β2-agonists less often. The study indicated that a blockage 
of leukotriene receptors in the airway can be therapeutically 
effective in some patients with EIB. Tolerance was not seen 
with continued montelukast treatment during the 12 weeks of 
treatment. The effect of this medication on exercise induced 
asthma was essentially the same at the beginning and end 
of the study. In addition no rebound effect was seen after 
montelukast was discontinued (Figure 3).
The initial multiple dose montelukast pediatric EIA 
study was performed in 6–14 year olds in a double blind, 
multicenter, placebo controlled, two-period crossover study.86 
Children received a 5 mg chewable montelukast tablet once 
daily instead of the 10 mg adult dose. The first exercise chal-
lenge was performed after two days of dosing. A standard 
exercise challenge (as described before) was done 20–24 hours 
after the last dose of montelukast or placebo. At least a four 
day interval occurred between the two treatment periods in 
this crossover study. In these 6–14-year-old subjects, a similar 
attenuation of the effects of exercise was seen as in the adult 
study (Figure 4). The maximum decrease in FEV1 in the 
placebo patients was about 24% whereas it was 13% in the 
montelukast-treated group. As in the adult study, the mon-
telukast patients returned to baseline FEV1 faster with less 
need for β2-agonist rescues than the subjects given a placebo. 
Since it is customary in the US for the FDA to require two 
separate studies to obtain a new indication for a medication 
(montelukast for 6–14 year olds with EIB), an additional study 
is being completed to obtain this indication for children.
With an appropriate antigen inhalation challenge, most 
allergic asthma patients will have an immediate asthma reac-
tion within a few minutes following the challenge. This is 
thought to be the result of the release of preformed mediators 
from airway cells. In addition following the immediate reac-
tion and a return to baseline, some subjects will have a delayed 
reaction 3–5 hours later, with a corresponding fall in FEV1. 
0
–5
–10
–15
–20
–25
–30
–35
–40
15 30 45 60
Montelukast (n = 52) 
Placebo (n = 54) 
Minutes after exercise 
C
h
a
n
g
e
 
i
n
 
F
E
V
1
 
(
%
)
0 5 10
Figure 2 Mean (±Se) changes in Fev1 after exercise challenge after 12 weeks of 
treatment with montelukast or placebo.  Treatment with montelukast was associated 
with a significant (P = 0.002) reduction in exercise-induced bronchoconstriction.
Abbreviation: Fev1, forced expiratory volume in one second.Therapeutics and Clinical Risk Management 2009:5 929
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This late reaction is believed to be the result of inflammatory 
cell migration into the airway.87 There is no consensus that a 
delayed response to exercise occurs in EIB,88,89 however such 
a reaction has been reported in some studies.90,91 Attenuation 
of a late response following exercise in the laboratory would 
give further insights on the mode of activity of a therapeutic 
agent such as montelukast and the role of leukotrienes in the 
process of inflammatory airway diseases such as EIB.
In a small double-blind randomized pediatric EIB 
study, montelukast was shown to block a late reaction 
that had occurred in five subjects.92 These subjects were 
aged 7–16 years. Although only five of the 22 subjects 
enrolled in the study demonstrated a late phase response to 
exercise, once-daily treatment with montelukast 5 mg for 
one week attenuated the immediate response and abolished 
the late phase response in these five subjects. This effect 
was independent of the use of ICS. Since leukotrienes are 
released during the immediate and late phase of an allergic 
reaction, such an attenuation of  both responses demon-
strates that leukotrienes in the airway have more than just an 
immediate effect on airway smooth muscle. They also are pro-
inflammatory mediators that are involved in the late reaction.
The majority of clinical studies with montelukast looked 
at its effect on EIB after at least two days of dosing. The 
positive effects seen are important for patients with more 
persistent asthma who take controller therapy daily for 
symptom control. The effect of a single dose of montelukast 
in patients who only have EIB and do not take medication 
daily was evaluated in a study that demonstrated that an 
initial single dose of montelukast was able to attenuate the 
effect of exercise two hours after administration.16 This was 
a double-blind crossover study in 62 patients with EIB. 
Challenge was performed 2, 12, and 24 hours after a 10 mg 
montelukast dose. The primary end point was the maximum 
percent fall in FEV1 during 60 minutes after exercise. This 
end point was improved in the montelukast patients: 10.8% 
decrease in FEV1 at two hours, 8.4% at 12 hours, and 8.3% at 
24 hours post-dose compared to the placebo patients: 22.3% 
decrease in FEV1 at two hours, 16.1% at 12 hours, and 16.9% 
at 24 hours. Less patients in the montelukast group required 
β2-agonist rescue. A quicker time to recovery after challenge 
was found in the montelukast patients as was a smaller area 
under the curve for percent fall in FEV1 during 60 minutes 
after challenge.
The duration that a medication can attenuate EIB is 
important to many athletics and patients who may exercise 
at different times of the day or who do not wish to take 
medication immediately before exercise. SABAs have been 
used for years to prevent the effects of exercise in patients 
with EIB. However, they usually have duration of effect of 
only 2–4 hours which may not adequately protect the indi-
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vidual who may wish to exercise late in the day or at school 
following a morning dose of medication. Studies with LABAs 
have shown a protective effect on EIB of 10–12 hours,57,62 
which makes them a much better therapeutic choice in 
such situations. However as discussed previously, with the 
regular use of LABAs tolerance is common, resulting in a 
decrease in duration of protection.93,94 Since LTRAs have 
shown protection against EIB for 24 hours, how do they 
compare with LABAs in clinical studies?
In order to study the protective effect of a LTRA with 
a LABA, a three-way crossover study with montelukast, 
salmeterol, and placebo was done in 47 patients aged 
15–44 years with demonstrable EIB.95 FEV1 was measured 
at 2, 8.5, and 24 hours post-dose. The results of this study 
showed that both montelukast and salmeterol protected 
against the effects of exercise at two and 8.5 hours post-
dose, but the protective effect of salmeterol had subsided 
by 24 hours (Figure 5). Montelukast patients still showed 
protection 24 hours post-treatment.
In another study, adults taking ICS with who continued 
to demonstrate EIB were either randomized to salmeterol 
bid or montelukast once daily for four weeks. At the end 
of the study montelukast patients not only showed less fall 
in FEV1 following exercise but had a greater response to 
a SABA (salbutamol, albuterol) when bronchoconstrictor 
rescue was needed.96 This would confirm previous studies that 
show the development of tolerance with regular β2-agonist 
use. In a pediatric study of 32 children aged 6–12 years with 
EIB, tolerance to the protective effect of 5 mg montelukast 
daily over a four-week treatment period was not found.97 The 
children exercised 20–24 hours after dosing after 3, 7, and 
28 days of medication. Montelukast decreased the fall in 
FEV1 by about 50%, whereas there was no change in FEV1 
in children taking a placebo. It is important to remember that 
not all patients in a clinical trail respond equally.
Often what is reported or focused upon are the mean 
responses of the group. Clearly there are many patients who 
do better than the mean and many who do worse. Often 
the responder and nonresponder patients, when plotted on 
a graph, form a bell-shaped curve which might be quite 
symmetrical with approximately 50% responders and 50% 
nonresponders. This is true with many diseases and has been 
demonstrated in both persistent asthma98,99 and EIB.85,86 
There may also be the inability of an active medication 
to be effective in all clinical situations. For example, no 
effect was seen in a study of the effect of montelukast in 
the prevention of asthma-like symptoms in elite ice hockey 
players.100
One of the reasons patients or patient groups respond 
differently to a specific medication is very likely to be because 
of gene polymorphism. Two recent studies looked at gene 
polymorphisms in patients with EIB.101,102 In one of the stud-
ies it was demonstrated that Korean children with EIB had 
better response to a LTRA if they had a particular gene which 
resulted in a mechanism of inflammation (interleukin-13 [IL-
13]) that was more likely to involve leukotrienes. Therefore, 
no matter what treatment is chosen, it is important to have 
the patient with EIB return to the clinic for a reevaluation in 
2–4 weeks as responses vary.
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During clinical trials of montelukast, very few adverse 
effects were reported by patients or found from review of 
laboratory test results. Most of the findings were similar to 
those found in placebo-treated patients and were commonly 
found in all patients: upper respiratory infection, sinusitis, 
headache, and cough. Shortly after marketing, reports of 
a severe vasculitis called Churg–Strauss syndrome (CSS) 
began to appear in some patients taking montelukast and 
other leukotriene-modifying medications. Although the FDA 
issued a warning about this syndrome appearing in patients 
taking leukotriene-modifying medications, the possibility 
that this condition might be the direct result of treatment 
with these agents remains unproven. No epidemic of CSS 
has developed since millions of doses of medications were 
prescribed over a decade of use. Although isolated cases 
of CSS have continued to be reported and some devel-
oped after patients were started on leukotriene-modifying 
therapy, the general consensus is that CSS was already 
present in the majority of cases before treatment with these 
new medications. It has been proposed that in many cases 
the reason CSS appeared was attributable to a decrease or 
elimination of systemic corticosteroids being used to treat 
this previously undiagnosed condition which often is associ-
ated with very severe asthma.103,104 However, this issue has 
not been resolved and in a review of 62 cases available on 
Medline as of 1997, the authors concluded that available 
evidence suggests an association between LTRA and CSS 
that may be causal.105
Recently reports of rare occurrences of neuropsy-
chiatric events have been reported in patients taking 
montelukast, zafirlukast, and zileuton. These include 
behavior- and mood-related changes (agitation including 
aggressive behavior, bad/vivid dreams, depression, feeling 
anxious, hallucinations, irritability, restlessness, suicidal 
thoughts and actions [including suicide], tremor, or trouble 
sleeping). As a result, the FDA106 and pharmaceutical com-
panies have included these findings in their prescribing 
information, although a cause-and-effect relationship has 
not yet been proven. Despite the general strong safety pro-
file obtained from a decade of use and the rarity of reported 
adverse events with montelukast, prescribers should always 
be aware that rare and unexpected events can happen and 
may later be found to be associated with this medication and 
therapy of any kind.
Conclusion
Although EIB is a common finding in both adults and 
children with asthma, it can occur in patients who only 
wheeze following exercise. Although there is much yet 
to learn about the pathophysiology of this disorder, it is 
becoming clearer that the bronchoconstriction experienced 
by the patient is a result of hyperventilation of any type on 
an injured inflamed airway. Understanding of this underlying 
mechanism is important not only in directing the patient to 
proper medications, but in directing them to an exercise 
program that can allow adequate cardiovascular benefits.
It is important not to assume that all patients who present 
with respiratory symptoms during or following exercise have 
EIB. Clearly patients may be “out of shape” or overweight, 
but it is important to think about cardiovascular disorders or 
other conditions that are result in upper airway obstruction 
such as vocal cord dysfunction. It is very difficult to evaluate 
a patient with airway symptoms without an objective 
measurement of airway function. Studies have shown 
both an under- and over-diagnosis of the degree of airway 
obstruction or loss of lung function when only the history 
and physical examination are used. Spirometry has become 
so readily available and inexpensive, that today any patient 
with persistent or recurrent respiratory problems should be 
evaluated with pulmonary function tests.
When spirometry is not available, a therapeutic trial of a 
medication which should be effective in EIB may be enough 
to make the diagnosis. However since often there is a 30% or 
greater response rate to placebos in most disorders, objective 
documentation of the effect of the medication is important. 
Not only is documentation of responses to medication in a 
condition such as EIB is extremely important, regular follow 
up must be part of a management program for patients of any 
age or level and type of exercise.
For many compliant patients, keeping good control 
of their asthma will be enough to allow them to exercise 
adequately. Fortunately several medications have been 
proven to be effective in this disorder. These include ICS, 
SABA, LABA, cromones, and more recently medications 
that modify the effect of leukotrienes in the airway. In this 
category, the LTRA, montelukast, has been the drug most 
studied and currently is approved for the control of EIB in 
patients aged 15 years and older in many countries. Studies 
have shown an effect as soon as two hours after a single 
10mg dose of montelukast. With multiple dosing, an effect 
can be demonstrated 24 hours after the last dose in many 
patients. Tolerance with repeated dosing has not been seen in 
clinical studies. Although reports of serious adverse effects 
have been reported in patients receiving montelukast and 
other leukotriene-modifying medications, the consensus 
is that there is little evidence of a causal relationship to Therapeutics and Clinical Risk Management 2009:5 932
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these medications. Clinical research studies and regulatory 
approvals indicate that the LTRA, montelukast, is a 
reasonable medication to consider in patients with EIB.
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